PharmaMar, S.A.
http://www.pharmamar.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From PharmaMar, S.A.
China Biotech Podcast: AACR, BIOSECURE European Perspectives
Guest Andrew McConaghie from Scrip's UK team joins Brian Yang and Dexter Yan to discuss AACR highlights from Chinese biotechs, European perspectives on the proposed US BIOSECURE Act, two recent acquisitions and Boehringer Ingelheim's recent quarterly results.
AACR: Akeso’s Cadonilimab Shows 1L Potential In Adenocarcinoma
With a clinical win in the Phase III COMPASSION-15 trial in gastric/gastroesophageal junction adenocarcinoma, Akeso's PD-1/CTLA-4-targeting agent is well positioned to expand its label beyond second- or third-line use for cervical cancer, and appears to stack up well against big global competitors. The Chinese firm is also aiming the bispecific antibody at hepatocellular and lung cancers.
Strong Sales, Deals Propel China Biotechs To 2023 Profitability
Strong sales growth and licensing activity in 2023 helped multiple Chinese biotechs to a solid profit performance, some moving into the black for the first time.
BeiGene’s Tevimbra And The End Of The COVID Inspection Era
US FDA approves the PD-1 inhibitor 20 months after user fee goal, resolving one of the last applications delayed by China’s extended pandemic travel restrictions.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- Grupo Zeltia
- PharmaMar
- Zeltia Group
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice